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Introduction
Leukocyte traffic is the hallmark of the immune
response. Controlled cell movements allow the precise
interactions necessary to bring different leukocytes
into physical contact. The possibility of rare T and B
lymphocytes encountering their specific antigen is
maximized by their recirculation through secondary
lymphoid organs, in which antigens are displayed to
them by antigen-presenting cells. Of these, dendritic
cells (DCs) are an important heterogeneous population
of antigen-presenting cells that can induce, sustain,
and regulate immune responses (1). Once activated,
effector T cells are able to migrate to tissues in which
pathogens have been detected. Eventually, memory T
cells constitute a surveillance system that ensures tis-
sue protection in case of a new antigen challenge. In
recent years, several reports have pointed to
chemokines as important factors in the regulation of
leukocyte trafficking, both in physiological and patho-
logical situations (2–7).
CCR6 is a b -chemokine–specific receptor for CCL20
(MIP-3 a /LARC/Exodus) (8–13). In addition to having
only one highly specific ligand, other features make
CCR6 an interesting receptor. Human (h)CCR6 is
expressed in immature DCs derived in vitro from
CD34+ precursors and is downregulated as DCs mature
(14, 15); it is also expressed in memory T cells, CLA+
cells, and B cells (16). Similar CCR6 expression patterns
have been reported in the mouse, in which CCR6 is
expressed in the myeloid but not in the lymphoid DC
subpopulation (17, 18), B cells and CD4+ T cells (17).
CCL20 is known to interact only with CCR6 in both
the human and murine systems. Human CCL20 trig-
gers adhesion of memory CD4+ T cells to ICAM-1 (19)
and is expressed in epithelial crypts of inflamed ton-
sils (14), epithelial cells from appendix (20), as well as
keratinocytes and venular endothelial cells from non-
pathological skin (21) and psoriatic skin (22, 23).
Murine CCL20 (mCCL20) was also reported to be
expressed in epithelial cells from intestinal tissue (20);
interestingly, in Peyer’s patches (PPs) mCCL20 is
expressed only by the follicle-associated epithelium
(FAE) overlying the subepithelial dome (SED), where
CCR6-expressing cells accumulate (18).
Taken together, these data suggest a role for CCR6
and its ligand as regulators of the migration and
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recruitment of antigen-presenting and immunocom-
petent cells during inflammatory and immunological
responses. Indeed, while this manuscript was in prepa-
ration, Cook et al. reported data on CCR6–/– mice
showing that this b -chemokine receptor is a regulator
of the humoral immunity and lymphocyte homeosta-
sis in the intestinal mucosa (24). We have also gener-
ated CCR6–/– mice to investigate the CCR6 role in vivo.
Analysis of these mice revealed defects in leukocyte
homing to the intestinal mucosa as evidenced by their
underdeveloped PPs, in which clear alterations in the
positioning of myeloid CD11b+ CD11c+ DCs were
observed. These animals also showed increased num-
bers of intraepithelial lymphocyte (IEL) subpopula-
tions. The altered responses of CCR6–/– mice in contact
hypersensitivity (CHS) and delayed-type hypersensi-
tivity (DTH) models of inflammation suggest addi-
tional roles for CCR6 in the activation and/or migra-
tion of CD4+ T-cell subsets.
Methods
Gene targeting. Gene targeting was performed according
to established methods (25). A 7-kb BamHI DNA frag-
ment containing the CCR6 gene was subcloned from a
phage P1 mouse genomic library (Genome Systems
Inc., St. Louis, Missouri, USA), as described (17). A 2.7-
kb PstI-EcoRI and a 2.7-kb SmaI-XbaI fragment from the
CCR6 gene 5 ¢ and 3 ¢ regions, respectively, were then
subcloned at either end of a neomycin resistance gene,
under the control of the phosphoglycerate kinase pro-
moter. The herpes simplex thymidine kinase gene was
fused at the 5¢ end of the cloned CCR6 sequences in the
replacement targeting construct, which was then lin-
earized by NotI digestion and electroporated into the
129 SvJ R1 (26) embryonic stem (ES) cell line. Ganci-
clovir and G418-resistant clones were selected, and 10
m g of genomic DNA from each clone was BamHI
digested, subjected to electrophoresis, and blotted onto
Hybond-N+ membranes (Amersham Pharmacia
Biotech, Piscataway, New Jersey, USA). High-stringency
hybridizations with CCR6-specific 32P-labeled probes
were performed in Rapid-Hyb buffer (Amersham Phar-
macia Biotech). Probe A was derived from a region
upstream of the 5 ¢ homology region (Figure 1).
Three independent correctly targeted ES clones were
used to produce chimeric mice by aggregation with
CD1 morulae, which were then transferred to pseudo-
pregnant CD1 females, as described elsewhere (25).
Chimeric males were bred to C57BL/6, and the off-
spring genotype was analyzed by Southern blotting and
PCR with specific primers. Transcription of the CCR6
gene was analyzed by Northern blotting, using a DNA
fragment internal to the CCR6 coding sequence as
probe. Age- and sex-matched, 8- to 16-week-old 129 SvJ
· C57BL/6 F3 or F4 CCR6–/– animals were used
throughout this study; 129 SvJ · C57BL/6 F3 or F4
CCR6+/+ mice were used as controls.
Cell preparations. Mice were sacrificed by cervical dis-
location. Inguinal, axillary, and brachial (IAB) lymph
nodes (LNs), mesenteric LNs, PPs, spleen, and small
intestine were collected. The organs were gently dis-
rupted in RPMI with 10% FCS and filtered through
nylon mesh to remove aggregates. Splenocytes were
depleted of erythrocytes by lysis with 0.83% ammo-
nium chloride.
For IEL preparations, small intestine, free of fat, PPs,
and fecal content, was cut longitudinally. After two
washes with 30 ml of Ca2+- and Mg2+-free HBSS (CMF-
HBSS) containing 2% FCS and 10 mM HEPES, pH 7.2,
intestines were rinsed quickly with cold CMF-HBSS
containing 5% FCS and 5 mM EDTA. The samples were
then incubated (37°C, 30 minutes, with stirring) in
CMF-HBSS with 10% FCS and 5 mM EDTA. Super-
natants were then collected and intestines vortexed for
10 seconds in 40 ml of the same solution. Supernatants
were pooled and passed through a prewashed 10-ml
nylon wool column. The recovered cells were separated
in a discontinuous Percoll (Amersham Pharmacia
Biotech) gradient, and IEL were recovered from the
interface between the 67% and 44% layers.
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Figure 1
Targeted disruption of the CCR6 gene. (a) Targeting strategy. CCR6
WT locus with partial restriction map. The coding sequence (CDS),
neomycin resistance gene (Neo), and thymidine kinase gene (TK) are
shown as open, filled, and shaded boxes, respectively. A thick filled
bar shows probe A, used in Southern blot analysis for screening
genomic DNA. Arrows mark the position and direction of synthesis
of oligonucleotides used in PCR genotyping. B, BamHI; P, PstI; H,
HindIII; E, EcoRI; S, SmaI; X, XbaI; N, NotI; K, KpnI; O, XhoI. (b) Rep-
resentative Southern blot analysis of BamHI-digested tail DNA from
WT (+/+), heterozygous (+/–), and homozygous (–/–) CCR6 mice
using probe A. Band sizes in kilobases for the WT and knockout alle-
les are indicated on the left. (c) Representative Northern blot analy-
sis of the CCR6 mRNA expression in thymus and spleen from CCR6
WT (+/+) and knockout (–/–) animals. The size of the CCR6 tran-
script in kilobases is indicated on the left.
Flow-cytometry studies. The following FITC-, phycoery-
thrin- (PE-), Tri-color– (TC-), or SpectralRed- (SPRD-)
conjugated mAb’s from PharMingen (San Diego, Cali-
fornia, USA) were used in this work: anti-CD69
(H1.2F3), anti-CD3 (145-2C11), anti-CD4 (H129.19),
anti-CD8 (53-6.7), anti-B220 (RA3-6B2), anti-CD45
(30F11), anti-Thy1.2 (53-2.1), anti–TCR-ab (H57-597),
and anti–TCR- gd (GL3). Cell staining and flow cytom-
etry were performed in an EPICS XL flow cytometer
(Coulter Electronics Ltd., Hialeah, Florida, USA),
according to standard protocols.
Skin explants. Ear skin was split into dorsal and ven-
tral portions, and epidermal and dermal sheets were
prepared from dorsal portions, before (fresh skin) or
after 72-hour culture in complete RPMI-1640 media
(skin explants), as described (27).
Immunohistochemistry. Epidermal and dermal sheets
from ear (fresh skin or skin explants) were fixed in ace-
tone for 20 minutes. They were then sequentially incu-
bated with rat anti-mouse NLDC145 (LABGEN, Frank-
furt, Germany), followed by biotinylated goat anti-rat
IgG (H+L) (Southern Biotechnology Associates, Birm-
ingham, Alabama, USA), and streptavidin-Cy3 (Amer-
sham Pharmacia Biotech), or anti-Iab (AF.6-120.1;
PharMingen). All incubations were carried out in the
presence of 5% normal goat serum (NGS) and 1% BSA
in PBS; an avidin/biotin blocking kit (Vector Laborato-
ries, Burlingame, California, USA) was also used after
incubation with the primary Ab. Density of Langerhans’
cell (LC) population within dermal sheets was deter-
mined by direct counts of labeled cells in a defined area
of an ocular grid, magnifying · 100. Ten random fields
on sheets were counted for each animal.
Frozen PPs were cut in 10- m m sections, fixed in cold
acetone for 10 minutes, and stored at –80°C. PP sec-
tions were blocked (30 minutes) with 20% NGS, 1%
BSA in PBS, followed when necessary by incubation
with the avidin/biotin blocking kit. All Ab incubations
were performed in 1% NGS and 1% BSA in PBS. The
following Ab’s from PharMingen were used: biotiny-
lated anti-CD8, anti-CD11c (N418), anti-CD11b
(M1/70), and anti-B220-PE. In addition, anti-Thy1.2-
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Figure 2
Similar LC complements in the skin, but altered positioning of the
myeloid DC subpopulation within the PPs of CCR6–/– mice. (a) Sam-
ples of skin epidermis (panel 1) and dermis (panel 2) were stained
with the NLDC145 Ab and analyzed by fluorescence microscopy. In
panel 3, dorsal ear skin preparations were cultured for 72 hours in
RPMI-1640. Dermal sheets were then separated from epidermis and
stained with anti-Iab to reveal the existence of LC cords. (b) Stain-
ing of WT (CCR6+/+) and knockout (CCR6–/–) mouse PPs with anti-
B220 (red) and anti-Thy1.2 (green) reveals B cells in follicles (F) and T cells in the IFR. For orientation, lumen (L) position is indicat-
ed. In panel 2, staining with anti-CD11c (red) and anti-CD8 a (green) localizes lymphoid DC mainly in the IFR. In panels 3 and 4,
staining with anti-CD11c (red) and anti-CD11b (green) shows a defect in the positioning of myeloid DC in CCR6–/– mice, where they
are located mainly in the IFR and not in SED. Scale bars = 100 m m.
FITC (Becton Dickinson, Oxford, United Kingdom),
streptavidin-Cy2, and streptavidin-Cy3 (Amersham
Pharmacia Biotech) were used.
Subcutaneous immunization. Animals (8–10 weeks old)
were immunized subcutaneously in the dorsum with
30 m g dinitrophenyl–keyhole limpet hemocyanin
(DNP-KLH) in CFA, and boosted twice with 30 m g of
DNP-KLH in incomplete Freund’s adjuvant at days 10
and 28 after immunization. DNP-KLH–specific serum
Ab titers were determined by serial dilution of serum
in DNP-KLH–coated 96-well plates. Ab’s bound to
plates were developed with peroxidase-conjugated iso-
type-specific Ab’s (Southern Biotechnology Associates)
and diaminobenzidine (Sigma Chemical Co., St. Louis,
Missouri, USA).
Contact hypersensitivity. The mouse ear-swelling test has
been described elsewhere (28). Briefly, mice were sensi-
tized topically by applying 25 m l of 0.5% 2,4-dinitrofluo-
robenzene (DNFB; Sigma Chemical Co.) solution in ace-
tone/olive oil (4:1) to the shaved abdomen. Five days later,
20 m l of 0.2% DNFB in the same vehicle was applied to the
right ears, and vehicle alone to the left ears. Ear thickness
was measured with a dial thickness gauge (Mitutoyo
Corp., Kawasaki, Japan), and ear swelling was estimated
by subtracting the prechallenge from the postchallenge
value, and by further subtracting any swelling detected in
the vehicle-challenged contralateral ear.
Delayed-type hypersensitivity. Mice were sensitized by
intravenous injection of 106 BALB/c splenocytes, and
challenged on day 5 with 13 · 106 BALB/c splenocytes
(50 m l PBS) in the right footpads. Control left footpads
received 50 m l PBS. Right footpad swelling was calcu-
lated on different days by subtracting the prechallenge
value and any swelling measured in left footpads from
the postchallenge value.
For adoptive transfer experiments, cell suspensions
from LNs of BALB/c splenocyte-sensitized or untreated
control animals were depleted of B220+ and CD8+ cells
by incubation with rat anti-mouse B220-FITC and CD8-
FITC, followed by separation in MACS columns with
paramagnetic anti-FITC microbeads (Miltenyi Biotech,
Auburn, California, USA). Eluted CD4+ T cell–enriched
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Figure 3
CCR6–/– mice have underdeveloped PPs and impaired lymphocyte homeostasis in the intestinal mucosa. (a) Low-magnification microgra-
phy of dissected PPs from 4-month-old WT (CCR6+/+) and CCR6–/– mice showing the different level of development of these lymphoid organs.
(b) The number of PPs is similar in WT (CCR6+/+) and CCR6–/– mice. Data shown correspond to the average number found in ten animals
of each genotype. (c) The number of developed follicles per patch and the number of PPs with a given developmental state differ in CCR6–/–
mice (filled bars) from those of WT animals (open bars). Accumulated data are presented from ten animals per group. (d) Flow-cytometry
analysis of lymphocyte subsets in PPs of WT (open bars) and CCR6–/– mice (filled bars). (e) The cell numbers in IEL subpopulations are
increased in CCR6–/– mice (n = 2–3 pooled animals of each genotype in each experiment). Data shown in d and e correspond to the mean
and SE from five independent experiments.
preparations were injected into the tail vein of recipient
mice (2 · 107 cells/mouse). After 16 hours, mice were
challenged by injecting 13 · 106 BALB/c splenocytes
(without red blood cells) into the right footpads, and
swelling was monitored throughout the following days.
In vitro antigen-presentation assays. In vitro lymphocyte
proliferation to 2,4-dinitrobenzenesulphonic acid
(DNBS), the water-soluble analogue of DNFB, was car-
ried out as described (29). Briefly, IAB LNs from
CCR6–/– and wild-type (WT) littermate control mice,
untreated or sensitized with DNFB in the abdomen 5
days before, were collected and pooled. Mesenteric LNs
were also collected. LN cells were then cultured alone
or in the presence of DNBS (50 m g/ml). Polyclonal acti-
vation of lymphocytes was performed by incubating
LN cells with 5 m g/ml of Con A (Sigma Chemical Co.)
for 48 hours. All cultures were then pulsed with 1
m Ci/well of 3H-thymidine for 18 hours.
Allogeneic mixed lymphocyte reactions (MLR) were
performed as described (30). Stimulating cells were
BALB/c splenocytes, inactivated with 50 m g/ml of mit-
omycin C (37°C, 20 minutes). Responding cells were
WT or CCR6–/– lymphocyte pools from IAB LNs. Stim-
ulating and responding cells were cocultured (37°C, 72
hours) at different ratios, then pulsed with 1 m Ci/well
of 3H-thymidine for 24 hours.
Results and Discussion
Generation of CCR6–/– mice. The mouse CCR6 gene was
replaced by homologous recombination, using the tar-
geting strategy shown in Figure 1a. This procedure
deleted most of the exon containing the CCR6 coding
sequence, leaving only the nucleotides encoding the 25
COOH-terminal amino acids of the receptor. Southern
blot analysis of ES clones surviving selection in culture
allowed the detection of those that underwent homol-
ogous recombination. Morulae aggregations were car-
ried out with three targeted ES clones to generate
chimeric mice, selecting two independent animals that
transmitted the disrupted CCR6 allele through the
germline. Chimeras were mated with C57BL/6 mice,
and heterozygous animals from F1 and subsequent off-
spring were backcrossed for three to four generations
with WT C57BL/6 mice. Southern blot analysis of tail
DNA confirmed the CCR6 coding sequence deletion
(Figure 1b). Northern blot analysis also confirmed the
lack of CCR6 mRNA (Figure 1c).
Mice maintained under barrier isolation were healthy,
and bred according to Mendelian inheritance patterns.
No phenotypic differences were detected between the
two CCR6–/– mouse lines generated. Several organs,
such as spleen, thymus, and LNs, and their resident
leukocyte populations were examined, and no differ-
ences were found between CCR6–/– mice and the corre-
sponding WT animals. The hematological and bone
marrow profiles of WT and CCR6–/– mice were also sim-
ilar (results not shown).
CCR6–/– mouse skin has a normal LC complement, able to
migrate from the epidermis into the dermis. CCR6 is selec-
tively expressed among the different DC subpopula-
tions. In humans, CCR6 is expressed mainly in imma-
ture DCs (14, 15). Furthermore, the CCR6 ligand,
CCL20, was proposed to have a role in regulating the
constitutive trafficking of epidermal LCs (21), a fact
that has not been confirmed by others (22).
We addressed these issues by searching for differences
in the number of LCs between WT and CCR6–/– mice.
The LC population in epidermis from the ear (Figure 2a,
panel 1) or abdominal skin (not shown) was analyzed
using immunohistochemistry. Surprisingly, no differ-
ences were detected in the LC population between WT
and CCR6–/– mice; this was further confirmed when cells
in ten random microscopic fields were counted at a mag-
nification of · 100 (not shown). Similar results were
obtained when dermis was analyzed (Figure 2a, panel 2).
Local inflammatory responses induce LC to migrate
from the epidermis into the dermis, where they form
cords in dermal lymphatics, after which they migrate out
of the skin. Skin explants that allow the in vitro repro-
duction of this LC migration (27) were performed, and
the results showed that LC from CCR6–/– mice migrated
from the epidermis to the dermis, where they formed the
characteristic cell cords (Figure 2a, panel 3). Taken
together, these results show that LCs without a func-
tional CCR6 receptor are equally able to reach the skin
and egress from this tissue after being stimulated to
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Figure 4
Serum concentrations of antigen-specific immunoglobulins in ani-
mals immunized with DNP-KLH. CCR6–/– (n = 7; circles) and CCR6+/+
(n = 7; squares) mice were immunized subcutaneously with 30 m g of
DNP-KLH in CFA and boosted twice with 30 m g of DNP-KLH in IFA
at days 10 and 28 postimmunization. Mice were bled from the retro-
orbital plexus at days 7 and 14, then every 21 days, and serum con-
centration of DNP-KLH–specific Ig isotypes were determined using
ELISA. Individual data from the 10–3 dilution and the mean value for
each group are presented. Two-tailed t-test value for the IgG2b data
at day 35 is P = 0.0032; P > 0.05 for the rest.
migrate and suggest that the CCL20/CCR6 pair is not an
essential component in the control of physiological LC
trafficking to the skin. Nevertheless, the reported CCL20
and CCR6 upregulation in the skin of psoriatic patients
(22, 23) indicates that these proteins might play an
important role in skin pathologies.
CCR6-deficient mice have underdeveloped PPs with altered
positioning of the myeloid DC subpopulation and impaired
lymphocyte homeostasis in intestinal mucosa. In the mouse,
CCR6 is expressed by myeloid spleen DCs but not by
the lymphoid DC subset (17). A recent report (18) on
the localization of distinct DC subsets within the PP
showed that mCCL20 mRNA is expressed mainly in the
FAE. Correspondingly, CCR6 mRNA is strongly
expressed beneath the FAE, within the SED; in addi-
tion, mCCR6 is also detected under the SED, where fol-
licle B cells are located (18). Consistent with these
results, CD11b+ CD11c+ CD8 a – myeloid CCR6-
expressing DCs are located in the SED region and
absent from the interfollicular region (IFR), whereas
lymphoid CD11b– CD11c+ CD8 a + DC, which do not
express CCR6, are located in the IFR (18).
We looked for possible alterations in the localization
of these DC subpopulations in the CCR6–/– mice.
Frozen PP sections were stained with different markers,
and the results showed normal B- and T-cell distribu-
tion in the follicles and IFR, respectively (Figure 2b,
panel 1). Consistent with the results reported by Iwasa-
ki and Kelsall (18), CD11c+ CD8a + lymphoid DCs were
located in the IFR (Figure 2b, panel 2). The CD11b+
CD11c+ myeloid DCs showed altered distribution in
CCR6–/– mice (Figure 2b, panels 3 and 4), however, and
were present mainly in the IFR and not in the SED, as
was the case in WT animals.
These were not the only alterations detected in PPs
from CCR6–/– animals. Regardless of the age of the ani-
mals examined, PPs from CCR6–/– mice were systemat-
ically smaller, showing a lower number of developed
follicles than those from WT animals; nonetheless, the
number of PPs along the small intestine was similar in
both animal groups. Results from a representative
analysis are shown (Figure 3, a–c). These observations
were further substantiated by flow cytometry analysis
of PPs and small intestine lymphocyte subsets. No
alterations were found in the relative proportions of
the different lymphocyte subsets analyzed in PPs from
CCR6–/– mice, but, consistent with their reduced size,
our results revealed a twofold decrease in the number
R42 The Journal of Clinical Investigation | Volume 107
Figure 5
Altered response of CCR6–/– mice in contact hypersensitivity
inflammation. (a) CCR6–/– (n = 12; circles) and CCR6+/+ (n = 12;
squares) mice were sensitized by epicutaneous application of 25
m l of 0.5% DNFB solution on the shaved abdomen. Increases in
ear swelling were measured 24, 48, and 72 hours after challenge
with 20 m l of 0.2% DNFB on the ears. Individual data and the
mean value for each group are presented. Two-tailed t-test values
for DNFB data: P = 0.006 (24 hours), P = 0.005 (48 hours), P =
0.002 (72 hours). (b) Similar number of lymph node cells in
CCR6+/+ and CCR6–/– mice. Animals were sensitized with DNFB
(filled bars) or left untreated (open bars); 5 days later, lympho-
cytes from IAB (I+A+B) LNs were prepared and counted. (c)
CCR6–/– lymphocytes proliferate in response to specific and non-
specific stimuli. CCR6–/– and CCR6+/+ animals were sensitized with
DNFB (filled symbols) or untreated (open symbols); 5 days later,
cells from draining (I+A+B) or control mesenteric LNs were recov-
ered and cultured for 36 hours alone or in the presence of DNBS,
as indicated. Cultures were pulsed with 3H-thymidine for 18
hours, and cell proliferation was estimated. Similar experiments
were performed to measure in vitro responses to a polyclonal
stimulus, Con A. Each value represents the average of three sepa-
rate groups, consisting of pooled LNs from two mice. All assays
were performed in triplicate.
of total leukocytes estimated as CD45+ cells in PPs
from mutant mice (Figure 3d). B220+, CD3+, CD4+,
CD8+, TCR- a b , and CD69+ cells were all reduced
approximately twofold in CCR6–/– mice. Conversely,
when IEL subpopulations were examined, the results
(Figure 3e) showed that CCR6 mutant mice had an
overall twofold increase in total lymphocytes, with
greater increases in the CD4+ CD8+ double-positive,
CD4+, CD8+, TCR- a b , and especially the Thy1.2+
CD69+ cell subsets. No differences were detected in B
cells, estimated as B220+ cells, nor in TCR- gd cells.
Mucosal membranes of the intestinal tissue are con-
stantly exposed to antigens. The organized mucosa-
associated lymphoid tissues function as inductive sites.
M cells present in the FAE capture antigens and inter-
nalize them to the underlying lymphoid tissue, where
they can be processed and presented by macrophages,
DCs, and B cells, thus generating the immune
response. The altered position of the CD11b+ CD11c+
myeloid DCs outside the SED in CCR6–/– mice may be
a factor contributing to the impaired PP development
in these mice, reflected by both diminished cellularity
and number of developed follicles. Exposure to intes-
tinal flora is essential for the complete development of
the gut-associated lymphoid tissue (31). The alter-
ations detected in myeloid DCs in CCR6–/– mouse PPs
may thus provoke defects in the presentation mecha-
nism of flora or other antigens, impairing PP develop-
ment. In addition, B lymphocytes play an organogenic
role in mucosal immunity, as demonstrated by the
impaired development of PPs, FAE, and M cells in mice
lacking B cells (32). B-cell numbers are reduced in PPs
from CCR6–/– mice (Figure 3), but there is no definitive
proof as to whether this is a cause or an effect of PP
underdevelopment. Anyway, CCR6 is normally
expressed in both human and mouse B cells, thus mak-
ing possible a hypothetical role for this chemokine
receptor in PP organogenesis. Gene disruption of lym-
photoxins or their cognate receptors has also been
reported to affect PP development (33); the expression
level of these genes in CCR6–/– mice will be the subject
of future investigations.
While this manuscript was in preparation, Cook et al.
reported similar results on the altered positioning of
myeloid DCs within PPs and increases in the IEL sub-
populations of CCR6 mutant mice (24). There is
nonetheless discrepancy with our results in PPs, which
are normal in their CCR6–/– mice. The distinct genetic
backgrounds of the animals used in the two studies are
unlikely to be responsible for the difference, since this
PP phenotype was already detected in our F1 mice. It is
possible, however, that differences in the animal diets,
in which the presence of sensitizing antigens may
amplify differences in PP development between WT
and CCR6–/– mice, account for this discrepancy in
results. In addition, different bacterial loads in mice
could also explain the differences in PP development.
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Figure 6
CCR6–/– mice have a markedly diminished DTH response to allogeneic
BALB/c splenocytes. (a) CCR6–/– (n = 10; circles) and CCR6+/+ (n = 11;
squares) animals were sensitized by intravenous injection of 106 BALB/c
splenocytes. Five days later, mice were challenged by injecting 13 · 106
BALB/c splenocytes into their right footpads, and swelling was meas-
ured 24 hours later. Individual data and the mean value for each group
are presented. The two-tailed t-test value for these data was P =
0.000016. (b) In vitro MLR to allogeneic BALB/c splenocytes. Lympho-
cytes were prepared from IAB LNs from CCR6+/+ (filled squares) and
CCR6–/– mice (filled circles) and cultured in 96-well plates (2 · 105
cells/well) with increasing amounts of stimulator allogeneic BALB/c
splenocytes. After 72 hours, cultures were pulsed with 3H-thymidine for
24 hours and cell proliferation was estimated. Background proliferation
is also shown (open symbols). Each point represents the average value
of two separate groups, each consisting of pooled LNs from two mice.
Assays were performed in triplicate. (c) Adoptive transfer of sensitized
CCR6+/+ CD4+ T cells to CCR6–/– mice restores their ability to produce a
DTH response. Unsensitized CCR6+/+ and CCR6–/– mice were adoptive-
ly transferred with 2 · 107 CD4+ T cell–enriched preparations purified
from sensitized CCR6+/+ and CCR6–/– donors, as indicated. T cells from
CCR6–/– IAB LNs were also allowed to proliferate in an in vitro MLR
assay with BALB/c splenocytes before being injected to CCR6–/– hosts
(++). After 16 hours, animals were challenged with 13 · 106 BALB/c
splenocytes in footpads, and swelling was measured 24 hours later.
Humoral response to subcutaneous immunization. To ana-
lyze the possibility of a defective systemic humoral
response in CCR6–/– mice, animals received DNP-KLH
subcutaneously, and their serum DNP-KLH–specific Ig
levels were determined on different days. No differences
in antigen-specific IgM and IgG1 were detected between
WT and CCR6–/– animals (Figure 4). In contrast, some
minor differences in DNP-KLH–specific IgG2b levels,
lower in CCR6–/– mice, were detected (P = 0.0032; Figure
4). Antigen-specific IgG2a levels were higher in the
CCR6–/– animals, but these differences were not statisti-
cally significant (P > 0.05; Figure 4). Immunoglobulin
class-switch recombination occurs in mature B cells
after contact with antigen. Since B cells express CCR6,
it is conceivable that CCR6–/– B cells are affected in this
process, giving rise to the differences observed. In addi-
tion to antigen contact, it is thought that concomitant
cytokine signaling controls Ig isotype specificity in class
switching (34). It could thus be speculated that altered
cytokine levels might contribute to the minor abnor-
malities detected in the systemic immune response to
DNP-KLH in CCR6–/– mice.
CHS responses. CHS is a hapten-specific skin inflamma-
tion mediated by T cells. Most haptens give rise to an
oligoclonal T-cell response consisting mainly of CD8+
effector T cells, whereas CD4+ T cells have a downregula-
tory role in the CHS response (35, 36). To test the role of
CCR6 in CHS, mice were epicutaneously sensitized with
DNFB, and then challenged 5 days later by hapten appli-
cation to ear skin. With DNFB treatment, ear swelling
was greater and lasted longer in CCR6–/– mice (Figure 5a).
We looked for possible differences in lymph node cellu-
larity between WT and CCR6–/– mice. Animals were
untreated or sensitized with DNFB and, 5 days later, lym-
phocytes from IAB LNs were prepared and counted. The
results showed similar increases in cell numbers in LNs
from DNFB-treated WT and CCR6–/– mice (Figure 5b),
suggesting that similar sensitization responses had taken
place in both groups. As predicted, the number of lym-
phocytes in LNs from untreated animals was clearly lower
and similar in both groups (Figure 5b).
We also analyzed the specific proliferative response
of lymphocytes from sensitized animals. Cells pre-
pared from LNs were cultured alone or in the presence
of DNBS, a water-soluble form of the hapten, and cell
proliferation was determined. Again, no differences
were detected between WT and CCR6–/– animals (Fig-
ure 5c). Lymphocytes from IAB LNs of DNFB-sensi-
tized animals showed a clear proliferative response
only in the presence of DNBS; control IAB LN lym-
phocytes from unsensitized animals and mesenteric
LN lymphocytes, with or without DNBS, did not pro-
liferate. Finally, we studied the proliferative response
to a polyclonal antigen, Con A. In this case, lympho-
cytes from all LNs studied were equally able to prolif-
erate in the presence of the antigen (Figure 5c). These
results suggest that the afferent branch of the hapten-
induced inflammation response functions correctly in
CCR6–/– mice. In CHS, LC participation does not
appear necessary for T-cell sensitization (37); in any
case, as shown above, LC numbers in CCR6–/– animals
are apparently normal, as it is their ability to migrate
into the dermis. Interestingly, the increased and per-
sistent inflammation seen in CCR6–/– mice suggests
that it is the efferent phase of the CHS response that
is defective in these animals. Because CD4+ T cells are
responsible for downregulating the DNFB-induced
inflammation (35), and these cells express CCR6 (16,
17, 19), suppressor CD4+ T-cell control of the inflam-
matory process may be impaired in CCR6–/– mice.
DTH responses. In contrast to CHS, DTH is elicited by
CD4+ T cells with apparent downregulatory effects of
CD8+ T cells (36). The results observed in the CHS model
prompted us to study the behavior of CD4+ T cells from
CCR6–/– mice in a DTH model. Control WT and CCR6–/–
C57BL/6 animals were sensitized by intravenous injec-
tion of 106 allogeneic BALB/c splenocytes. Five days later,
13 · 106 BALB/c splenocytes were injected into the right
footpads, and local inflammation was measured. Results
at 24 hours showed that, in comparison with WT mice,
CCR6–/– mouse footpads developed significantly less
inflammation (Figure 6a). Lymphocytes from IAB LNs
from WT and CCR6–/– mice were prepared, and their spe-
cific proliferative response to allogeneic BALB/c spleno-
cytes studied in MLR assays. Lymphocytes from CCR6–/–
mice showed no proliferative defect (Figure 6b).
These results suggested that CD4+ T cells from
CCR6–/– mice were unable to elicit the efferent phase of
the DTH response. To address this question, similar
DTH experiments were performed in which CD4+ T
cell–enriched preparations purified from the LNs of
WT and CCR6–/– animals were adoptively transferred to
either WT or CCR6–/– unsensitized mice 16 hours
before footpad challenge. The results (Figure 6c)
showed that adoptive transfer of 2 · 107 CD4+ T cells
from sensitized WT animals to both WT and CCR6–/–
mice before challenge caused these animals to develop
a similar footpad inflammation. Conversely, when
CD4+ T cells from sensitized CCR6–/– donors were
transferred to WT and CCR6–/– mice, the hosts were
unable to develop an inflammation response upon
injection of BALB/c splenocytes. To be sure that
CCR6–/– T cells had been in contact with the antigen
before being adoptively transferred, purified T cells
from CCR6–/– IAB LNs were induced to proliferate in an
MLR assay with BALB/c splenocytes and then trans-
ferred to CCR6–/– mice. This procedure did not alter the
lack of inflammation response of the hosts (Figure 6c).
Taken together, these results strongly suggest that the
CD4+ T cells responsible for eliciting the DTH inflam-
matory response are defective in CCR6–/– mice. As com-
mented for the CHS results, this defect may be related
to an impaired activation and/or ability to migrate
from lymphoid organs to tissues.
In summary, the results reported here show that
CCR6 plays a role in the control of leukocyte home-
ostasis in the intestinal mucosa. The altered position-
ing of CD11b+ CD11c+ DCs in PPs may contribute to
R44 The Journal of Clinical Investigation | Volume 107
the differences observed in lymphocyte subsets in
CCR6–/– mice. In addition, migration may be impaired
in these CCR6–/– cells, contributing to the overall defect.
The altered responses observed in the CHS and DTH
assays suggest a defect in the activation and/or migra-
tion of the CD4+ T-cell subsets that downregulate or
elicit the inflammatory response, respectively, in these
inflammation models. Taken together, our data show
that CCR6 participates in both homeostatic and
inflammatory processes, implying that the in vivo role
of its ligand, CCL20, fits within both functional
chemokine subfamilies. The finding of nonredundant
biological roles for CCR6 underscores the usefulness of
CCR6–/– mice as a model for the study of inflammato-
ry diseases, not only for intestinal but also for cuta-
neous pathologies such as allergic contact dermatitis,
the common clinical form of CHS.
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